echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > As Ebola became famous in the first World War, the enterprise holding the banner of Hong Kong stock entered the scientific and technological innovation board again

    As Ebola became famous in the first World War, the enterprise holding the banner of Hong Kong stock entered the scientific and technological innovation board again

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, the listing application draft of science and technology innovation board submitted by kangxinuo biology Co., Ltd (hereinafter referred to as "kangxinuo") shows that it has entered the "inquired" state Source: Shanghai Stock Exchange official website is no stranger to this innovative vaccine enterprise As early as 2014, because of the successful development of the "first Ebola vaccine in Asia", kanghino, founded only five years ago, has made a great reputation and stood on the stage of the world's top-level innovative vaccine research and development; on March 28, 2019, kanghino knocked on the door of the Hong Kong stock exchange, setting off a surge in the stock price in the opening gongs; only about half a year later, that is, on October 14, 2019, it once again sounded to the science and Technology Innovation Board The horn of March At the moment when the application for listing on the science and technology innovation board has made positive progress, more news shows that kangxinuo has started the research and development of new coronavirus vaccine It is undeniable that since its establishment in 2019, conchino has shown a strong momentum But what is the actual force behind the bustle? 01 From the perspective of Ebola virus, Ebola virus vaccine is the number one brand of kangxino Back to 2014 On March 21 of that year, an acute infectious disease first appeared in Guinea, with an initial number of 49 cases Then at the end of March, cases of infection were found in neighboring Libya, and in Sierra Leone in May By June 18, 528 cases had been infected in the three countries, with a mortality rate of 64% This is the Ebola virus infection It is also this year that after the outbreak of Ebola in large areas in West Africa, countries will rise to the level of national security strategy to prevent and control such virus diseases In fact, this is not the first time the Ebola virus has attacked humans In the 1970s, this chilling virus emerged in Sudan and Zaire in Africa In 2000, Ebola virus broke out in Uganda In 2018, the Ebola outbreak in Congo was listed as a global health emergency By August 2019, there were 2934 confirmed and suspected cases in Congo, of which 1965 were dead and nearly 70% were dead With the virus raging, China joined in the development of the Ebola virus vaccine in the early years By the time of Ebola outbreak in Africa in 2014, the Institute of bioengineering of Academy of Military Medical Sciences, which has mature vaccine technology reserve, is in urgent need of an industrial transformation platform to launch Ebola vaccine in the laboratory This is where conchino came on stage At that time, the only adenovirus vector platform in China was the platform that kangxinuo planned to use to develop new tuberculosis vaccine "We have made TB vaccine The technical route is exactly the same as that of Ebola vaccine We have technical reserves and technical platforms, so we immediately pushed up the Ebola vaccine." Yu Xuefeng, founder of kangxinuo, said in an interview with the media In order to investigate and determine whether the clinical trial can be carried out smoothly, in late April 2015, yuxuefeng and his team rushed to Sierra Leone, Africa, which is in the period of outbreak and riot A few months later, 19 large boxes of Ebola vaccine were transported to China Serbia Friendship Hospital, and clinical trials began "Thrilling." Yu Xuefeng later described the experience in his memory Finally, at 10:00 a.m on October 20, 2017, the former State Food and Drug Administration (CFDA) announced on its official website, "approval of new drug registration application for recombinant Ebola virus vaccine (Ad5 EBOV)" This is the third Ebola vaccine in the world and the first one in Asia to enter human clinical practice Ad5 EBOV has also inadvertently become the first product of ConocoPhillips to be launched on the market, as well as the first Ebola virus vaccine approved for emergency use and national reserve in China This is a type 5 adenovirus vector Ebola virus disease vaccine, which can prevent Ebola virus by using recombinant replication defective human type 5 adenovirus vector to induce immune response It is reported that, compared with the competitive products of multinational pharmaceutical companies, the ad5-ebov of kangxinuo biology shows better stability and does not need ultra-low temperature storage conditions The freeze-dried preparation used for the vaccine has a one-year validity under the storage condition of 2-8 degrees It has better stability than the experimental vaccine of Ebola virus developed abroad, which must be stored at - 60 degrees ultra-low temperature It has great advantages in transportation and use in high temperature areas such as Africa Of course, it's because of this vaccine that was not in the development plan that conchino began to make its mark in the market 02 Science and technology innovation board, let's start again Unfortunately, the popularity of the Ebola virus vaccine did not bring direct benefits to conchino "The company's recombinant Ebola virus vaccine (adenovirus vector) products are currently in urgent use and will be used under the guidance of the relevant national health management departments in the future, and the company will arrange production according to the special needs of the country," kangxinuo party previously told the media The overall financial data of conchino is also hard to say beautiful The prospectus mentions that "there is no main business income during the reporting period, only occasional other business income" However, from 2016 to the first three quarters of 2019, the realized net profits are - 49.852 million yuan, - 64.4491 million yuan, - 138.2717 million yuan and - 93.4736 million yuan Data source: from the perspective of cost structure, at present, the largest investment of kanghino is R & D expenses According to the prospectus, from 2016 to the first three quarters of 2019, the R & D expenses of Conoco were 51633400 yuan, 68.1 million yuan, 113 million yuan and 94.5918 million yuan respectively, of which, the year-on-year growth in 2017 was 30% compared with that in 2016, over 70% in 2018, and even over 90% in the first three quarters of 2019 With high R & D investment, there are 15 vaccines under development in 12 disease areas (pneumonia, tuberculosis, Ebola virus disease, meningitis, pertussis, etc.) in the research pipeline of kangxinuo In addition to the vaccine of the Ebola virus (ad5-ebov), the company's core product of meningococcal vaccine (MCV) currently has two kinds (mcv2, MCV4) which have passed the phase III clinical trial, and mcv2 has been approved by the new drug application Source: Official Website of conchino Among them, mcv2 is a vaccine for the prevention of infection with Neisseria meningitidis (LTA) Compared with the currently approved mcv2 products in China, kangxinuo has shown better safety and immunogenicity in its three-phase clinical trials; MCV4 is the first vaccine in China, which is considered to be safe and well tolerated, and it has been shown in the age group of three months to six years old Good immunogenicity In addition, the two DTCP vaccines are expected to complete all clinical trials by 2020 At present, according to official wechat of Tianjin International Biomedical Joint Research Institute, "as a leading enterprise in the vaccine industry and a Hong Kong listed enterprise, kangxinuo mainly undertakes the research and development tasks of new coronavirus vaccine and pre clinical evaluation, carries out the evaluation of a variety of vaccine technologies to meet the emergency quickly, and develops key technologies such as virus vector vaccine, mRNA vaccine and recombinant protein vaccine." In other words, conchino has also been involved in the development of new coronavirus vaccines As the research and development progress of the new coronavirus vaccine has not been further disclosed, there is no more work here Back to the event of "science and technology innovation board listing", if it lands on science and technology innovation board successfully, kangxinuo will undoubtedly be the first stock of vaccine concept of "Hong Kong stock + science and Technology Innovation Board" At present, according to the latest data as of the closing on February 20, the Hong Kong stock market of conchino is worth HK $18.3 billion, with a share price of HK $82 / share Compared with the issue price of HK $22 / share on March 28, 2019, the share price of kanghino has achieved a rapid growth of nearly four times Data source: can the story of kangxinuo in Hong Kong stock exchange be rewritten on science and technology innovation board? Let's see Penicillin
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.